Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer
详细信息 查看全文
- 作者：Birgit E.P.J. Vriensa ; Bart de Vriesb ; Marc B.I. Lobbesc ; Saskia M. van Gasteld ; Franchette W.P.J. van den Berkmortele ; Tineke J. Smildef ; Laurence J.C. van Warmerdamg ; Maaike de Boerh ; Dick Johan van Spronseni ; Marjolein L. Smidtj ; Petronella G.M. Peerk ; Maureen J. Aartsa ; Vivianne C.G. Tjan-Heijnena ; vcg.tjan.heijnen@mumc.nl" class="auth_mail" title="E-mail the corresponding author ; on beha lf of the INTENS Study Group
- 关键词：Breast cancer ; Neoadjuvant chemotherapy ; Ultrasound (US) ; Magnetic resonance imaging (MRI)
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：52
- 期：Complete
- 页码：67-76
- 全文大小：689 K
文摘
- bel">•
Magnetic resonance imaging (MRI) and ultrasound (US) showed comparable agreement with post-therapy pathological tumour size.
- bel">•
MRI estimated residual tumour size with <10-mm discordance in 54% of patients.
- bel">•
US estimated residual tumour size with <10-mm discordance in 63% of patients.
- bel">•
US has the advantage of lower cost and wider availability compared to MRI.
- bel">•
Imaging post-therapy showed a low negative predictive value in hormone receptor-positive tumours.